FSANZ Board Communiqué Details Key Regulatory Updates for Food Sector

FSANZ Board Meeting Highlights: What Manufacturing Needs to Know

The Food Standards Australia New Zealand (FSANZ) Board has released its latest Communiqué, providing an essential overview of key decisions and discussions from its September 2025 meeting. For manufacturers in the supplement and wider food industry, these updates are not merely procedural; they signal critical shifts in regulatory expectations and open avenues for product development.

As contract manufacturers like Supplement Factory, we understand the paramount importance of staying ahead of such announcements. They directly influence everything from raw material selection to final product compliance. The Communiqué’s publication, a regular feature since October 2024, aims to enhance transparency within the joint Australia New Zealand Food Regulation System, giving both businesses and consumers a clearer view of the regulatory body's priorities.

Key Approvals with Industry Implications

• Egg Food Safety and Primary Production: A significant approval cited in the Communiqué relates to new egg food safety and primary production requirements (Proposal P1060). For supplement brands utilising egg-derived proteins or other egg components, this mandates a review of their supply chain and quality assurance processes to ensure compliance with updated primary production standards.
• Thermolysin as a Processing Aid: The approval of thermolysin (Application A1288) as a processing aid in a range of foods is particularly noteworthy. From a formulation standpoint, the introduction of new approved processing aids can streamline production, improve efficiency, or even enable novel product textures and forms within the wider food and beverage sector. While not directly a supplement ingredient, approved processing aids often reflect evolving regulatory comfort with enzymatic technologies that could indirectly impact ingredient development in the future.
• Review of Human-Identical Milk Oligosaccharides (HMOs): The Communiqué also shared outcomes from a 5-year review on human-identical milk oligosaccharides in infant formula (Application A1155). This long-term evaluation of a biologically active compound highlights FSANZ's commitment to rigorous scientific assessment for novel ingredients. Brand owners in the nutraceutical space should view this as an indicator of the extensive scientific backing and regulatory scrutiny required for any ingredient making functional claims, especially those targeting vulnerable populations like infants.

The Board's agenda also included insights from its annual risk workshop and bid farewell to three long-serving members, signifying an ongoing refresh of perspective within the regulatory body. These behind-the-scenes activities underscore a continuous process of risk assessment and adaptation, which ultimately shapes the regulatory environment we all operate within.

The regulatory landscape is ever-evolving. Remaining informed of FSANZ's decisions is not just about compliance; it's about anticipating future market trends and ensuring competitive advantage through proactive innovation. – Supplement Factory Editorial Team

The next FSANZ Board meeting is scheduled for 29 October, and manufacturers are encouraged to monitor future Communiqués. Embracing these regulatory shifts early allows for timely adaptation in product development and market strategy, ensuring continuous compliance and consumer confidence.

Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.